Skip to main content

Mutual Pharmaceutical v. Bartlett

Updated Oct 19, 2026

In brief

The Supreme Court ruled for Mutual Pharmaceutical: federal law blocks state design-defect claims when they turn on whether a drug’s warnings were adequate.

Where it stands
Decided

Decided 5-4 · June 24, 2013 · Opinion by Justice Alito

What it’s about
Karen Bartlett brought a New Hampshire design-defect claim against generic-drug maker Mutual Pharmaceutical.
Who it affects
State design-defect claims against generic-drug makers cannot go forward when liability turns on whether the drug’s warnings were adequate.

Summary: written with AI from the case record.

Illustration for Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett
Conceptual illustration · AI-generated

What it's about

The Supreme Court ruled that federal law blocks design-defect claims when they turn on whether a drug’s warnings were adequate, overturning the First Circuit’s ruling.

The Court applied PLIVA, an earlier case about federal law and generic-drug warning claims, to Bartlett’s design-defect case.

Question presented

Does federal law preempt a state design defect claim against a generic drug manufacturer?

What the Court decided

Holding

State-law design-defect claims that turn on the adequacy of a drug’s warnings are pre-empted by federal law under PLIVA. Pp. 6– 20. 678 F. 3d 30, reversed.

Result
Reversed

The Court's reasoning

The Court applied its PLIVA decision, concluding that federal law overrides state design-defect claims when they depend on whether a drug’s warnings were adequate.

The vote

  • Joined the judgment
  • Dissented
  • Wrote an opinion
Majority · 5joined the Court's opinion
  1. Thomas
  2. Scalia
  3. Kennedy
  4. Roberts
  5. Alitowrote the opinion
Dissenting · 4disagreed with the result
  1. Breyerwrote a dissent
  2. Kagan
  3. Ginsburg
  4. Sotomayorwrote a dissent
5 justices joined the judgment, 4 dissented.

From the opinions

“Today, the Court unnecessarily and unwisely extends its holding in Mensing to pre-empt New Hampshire’s law governing design-defects with respect to generic drugs.”

— Justice Sonia Sotomayor(dissent)

What's next

The Supreme Court has finished its work on this case; no further step is stated.

Documents

1

Docket activity

9
  • New analysis added

    Oct 19, 2026 · Court records

  • AI analysis generated: Impact Analysis

    Oct 19, 2026 · Generated

  • AI analysis generated: Opinion Summary

    Oct 19, 2026 · Generated

  • New analysis added

    Oct 19, 2026 · Court records

  • AI analysis generated: Case Briefing

    Oct 19, 2026 · Generated

Show 4 more
  • AI analysis generated: Decision Record

    Oct 19, 2026 · Generated

  • Case data updated: summary, question_presented, generation_metadata

    Oct 19, 2026 · Court records

  • Case data updated: question_presented, extraction_metadata

    Oct 17, 2026 · Court records

  • Opinion added: Bartlett

    Jun 24, 2013 · Court records

More questions

1
What did the justices who disagreed argue?
Justice Breyer and Justice Kagan said Mutual could comply with both laws by leaving New Hampshire or paying state damages, but that could still undermine federal goals. Justice Sotomayor and Justice Ginsburg said Bartlett’s design-defect claim was distinct, not a failure-to-warn claim in disguise.

Sources

Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.

Checked Oct 19, 2026Methodology

Court records and filings

Reporting and analysis